Develops AAV gene therapies for inherited retinal diseases, neurodegenerative disorders and salivary gland disease.
Develops AAV gene therapies for inherited retinal diseases, neurodegenerative disorders and salivary gland disease.
Has no product on sale; income so far has come from partnership payments rather than sales, and trials are funded by those deals and investor money. It makes its own gene-therapy vectors at in-house plants rather than relying on contract manufacturers.
Moat: narrow (IP / patents, process know-how). Vertically integrated in-house AAV manufacturing platform across multiple gene therapy indications.
Headquarters: New York City, US · Founded: 2015 · Employees: 403
Size MeiraGTx (MGTX) is a United States Health Care company (Biotechnology) with a market value of $813M, the 2359th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.32 on 18 Nov 2026.
Performance Over six months the shares fell 13.2%, against -15.8% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 1,365.9% over the last twelve months (peer median +1.1%); the operating margin is 44.5% (peer median -61.7%).
Valuation It trades at 1.9× enterprise value to sales against a peer median of 6.6× (2nd cheapest of 18).
Capital Return on invested capital runs 76.0 points above its cost of capital (9.8% WACC).
Short interest Short interest is 6.9% of the free float (30 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $402M | $81.4M | $33.3M | $14.0M | $15.9M |
| Revenue growth | — | +145% | +137% | -12% | — |
| Gross profit | $379M | $64.0M | -$3.34M | $287,000 | $7.20M |
| EBITDA | $191M | -$94.8M | -$151M | -$123M | -$108M |
| Net income | $78.3M | -$114M | -$148M | -$84.0M | -$130M |
| Free cash flow | -$2.99M | -$50.2M | -$109M | -$126M | -$118M |
| Capital expenditure | $4.75M | $4.24M | $4.96M | $20.2M | $45.0M |
| Total debt | $134M | $88.7M | $84.8M | $89.3M | $92.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| MeiraGTx MGTX | $813M | -13% | +1,366% | 44% | 1.9× | n/a |
| 4D Molecular Therapeutics FDMT | $578M | +23% | +79,952% | -226% | 3.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MGTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.6% | -6.9% | 6th lowest of 21 |
| 6-month return | -13.2% | -15.8% | 8th highest of 19 |
| Distance from 52-week high | -45.8% | -44.5% | 9th lowest of 21 |
| Revenue growth (TTM) | +1,365.9% | +1.1% | highest of 16 |
| Operating margin | 44.5% | -61.7% | highest of 18 |
| EV / Sales | 1.9× | 6.6× | 2nd cheapest of 18 |
| ROIC minus cost of capital | +76.0 pp | -11.1 pp | highest of 12 |
| EV / EBITDA | 4.0× | n/a | — |
| Net debt / EBITDA | -0.3× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |